Loading…

Cosmo N.V.CMHC.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Pharmaceuticals: Major

Swiss-listed specialty pharma focused on gastrointestinal drugs and endoscopy technology, using its MMX drug-delivery platform.

Momentum laggard 10
Mkt cap
$1.13B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$1.88M
20-day average traded
Fwd P/E
418.7×
forward earnings
ROIC−WACC
-11.6 pp
WACC 8.8%
Hurdle
n/a
no reverse DCF
Next earnings
126 days
24 Mar 2027
Close · CHFCHF 55.50
1D-1.8%
1W-3.3%
1M+4.9%
3M-3.8%
6M-30.1%
YTD-47.2%
1Y-14.8%
ATR %4.2%
52w lowhigh57.1% off high

What Cosmo does

Swiss-listed specialty pharma focused on gastrointestinal drugs and endoscopy technology, using its MMX drug-delivery platform.

Products and services

  • GI drugs (e.g., Aemcolo)
  • MMX drug-delivery licensing

Customers

  • Gastroenterologists
  • Pharma licensing partners

Where it sits in the supply chain

  • Biopharmaceuticals
  • Gastroenterology
  • Drug delivery (MMX)

What could go right

  • Licensing royalties from partners

What could go wrong

  • Small pipeline concentration

Moat: narrow (IP / patents). Patented MMX colon-targeted delivery technology licensed to pharma partners.

Headquarters: Zug, Switzerland · Employees: 324

Named competitors

Cosmo at a glance

Size Cosmo (CMHC.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $1.13B, the 116th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 55.50 on 18 Nov 2026.

Performance Over six months the shares fell 30.1%, against -9.7% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue fell 44.7% over the last twelve months (peer median +5.9%); the operating margin is -13.3% (peer median 4.5%).

Valuation It trades at 418.7× forward earnings against a peer median of 18.2× (most expensive of 11).

Capital Return on invested capital runs 11.6 points below its cost of capital (8.8% WACC).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 93CMHC.SW 69
Six months, rebased to 100: Cosmo against the median of its 20 peers (local-currency closes).

Cosmo financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 95.0MCHF 97.6MCHF 254MCHF 90.1MCHF 102M
Revenue growth—-62%+182%-12%—
Gross profitCHF 43.3MCHF 45.4MCHF 209MCHF 50.3MCHF 57.8M
EBITDA-CHF 559,550CHF 2.19MCHF 150MCHF 7.83MCHF 40.2M
Net income-CHF 5.85M-CHF 3.38MCHF 127M-CHF 10.5MCHF 17.3M
Free cash flow-CHF 22.5M-CHF 14.8MCHF 151MCHF 15.4MCHF 26.6M
Capital expenditureCHF 4.64MCHF 5.12MCHF 5.39MCHF 4.27MCHF 7.34M
Total debtn/aCHF 3.97MCHF 2.07MCHF 1.71MCHF 178M

Quarterly statements and history in the cockpit →

Cosmo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%0025500062804547VIYASH237690VETOPYC000989MEDCL600812OMER6855NKTR6884436883216880623000062616CMHC.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Cosmo is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×200×400×002550006280VIYASH237690000989688321CMHC.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cosmo is the large dot.

Cosmo competitors and peer comparison

Head to head with its named competitors (CMHC.SW vs BHC.TO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Cosmo CMHC.SW$1.13B-30%-45%-13%418.7×n/a
Bausch Health Companies BHC.TO$3.27B+66%+10%27%2.0×-14.8%

How Cosmo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cosmo against its 20 peers (data as of 18 Nov 2026)
MeasureCMHC.SWPeer medianRank in peer set
1-month return+4.9%-2.0%6th highest of 21
6-month return-30.1%-9.7%6th lowest of 20
Distance from 52-week high-57.1%-33.1%5th lowest of 21
Revenue growth (TTM)-44.7%+5.9%lowest of 18
Operating margin-13.3%4.5%9th lowest of 19
Forward P/E418.7×18.2×most expensive of 11
ROIC minus cost of capital-11.6 pp-4.6 pp8th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%32.2×36.3%+20.4%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%27.8×4.2%+21.7%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%n/an/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a
Mabwell (Shanghai) Bioscience 688062.SSChina$1.20B-46%+15%-129%n/an/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%n/a44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%n/an/an/a

Questions

Who are Cosmo's main competitors?
Named competitors: Bausch Health (BHC.TO). The cockpit's measured peer set (industry) also includes Changzhou Qianhong Bio-Pharma (002550.SZ), GC Biopharma (006280.KS), Kissei Pharmaceutical (4547.T), Symbiotec Pharmalab (SYMBIOTEC.NS), Viyash Scientific (VIYASH.NS), ST Pharm (237690.KS).
Is Cosmo expensive compared with its peers?
On forward p/e it trades at 418.7× against a peer median of 18.2×, most expensive of 11 in its peer set.
How has Cosmo stock performed?
Over six months to 18 Nov 2026 the shares returned -30.1% against -9.7% for the median peer; over one year -14.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.